Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corp (LFVN) delivers science-driven health solutions through nutrigenomic research and dietary supplements. This news hub provides investors and stakeholders with essential updates on corporate developments, product innovations, and market positioning in the nutraceutical industry.
Access timely regulatory filings, earnings reports, and press releases alongside analysis of scientific advancements. Our curated collection includes updates on weight management systems, cognitive enhancement products, and dermatological solutions backed by gene expression research.
Key content categories cover financial performance metrics, research partnerships, product launch details, and corporate governance updates. Bookmark this page for streamlined access to verified information supporting informed decisions about LFVN's market activities.
LifeVantage Corporation (LFVN) reported its fourth-quarter and full-year results for fiscal 2022, revealing a 7.0% revenue decline to $50.9 million in Q4 and a 6.3% drop to $206.4 million for the full year. Active accounts decreased 8.2% to 156,000. The company experienced a net loss of $1.4 million ($0.11 per diluted share) in Q4, compared to a net income of $4.9 million ($0.35 per diluted share) in the previous year. Adjusted EBITDA was $1.7 million in Q4, significantly down from $6.6 million a year earlier. Fiscal 2023 guidance suggests revenue will range from $200 million to $212 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the fourth quarter and full fiscal year ending June 30, 2022, on August 23, 2022, after market close. A conference call for investors is scheduled at 2:30 PM MT (4:30 PM ET) on the same day. Investors can participate via phone or listen to a live webcast, with archived access available for 30 days. LifeVantage specializes in nutrigenomics, including dietary supplements and health products like Protandim® and Petandim®.
LifeVantage Corporation (Nasdaq: LFVN) hosted Activate 2022, attracting over 6,000 distributors, marking a strong return to in-person gatherings post-pandemic. The event unveiled TrueScience® Liquid Collagen, featuring a rare Ruby Red Quinoa Extract, which enhances collagen synthesis by 42% and increases antioxidant levels by up to 202%. This product aims to differentiate LifeVantage in the nutrigenomics space by activating natural collagen production.
LifeVantage Corporation (Nasdaq: LFVN) has announced a new quarterly cash dividend of $0.03 per share, set to be paid on May 31, 2022. Shareholders of record as of May 17, 2022 will be eligible for this dividend. The company is noted for its nutrigenomics focus, providing a range of health products including dietary supplements and wellness solutions. This dividend initiation is a significant move, indicating the company's commitment to returning value to its shareholders.
LifeVantage Corporation (Nasdaq: LFVN) reported Q3 FY2022 results with revenues of $50.0 million, a 3.0% year-over-year decline. Total active accounts decreased by 6.5% to 157,000. Earnings per diluted share fell to $0.09 from $0.12 a year ago. The company announced a quarterly dividend of $0.03 per share. Adjusted EBITDA decreased 29.2% to $3.4 million. Fiscal 2022 revenue guidance was lowered to $204-$207 million from $212-$220 million, while adjusted EBITDA guidance was also reduced to $15 million from $18-$20 million.
LifeVantage Corporation (Nasdaq: LFVN) will release its financial results for the third quarter ending March 31, 2022, on May 3, 2022, after market close. A conference call for investors will take place at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can join via phone or a live webcast, which will also be available for replay until May 10, 2022. LifeVantage specializes in nutrigenomics, offering products like Protandim® and other dietary supplements aimed at promoting health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced the appointment of Cindy Latham to its Board of Directors, bringing over 30 years of experience in global marketing and product development in the direct selling sector. Chairman Garry Mauro applauded her proven leadership and industry expertise, indicating a positive outlook for company growth. Latham expressed her commitment to leveraging LifeVantage's brand strength to develop new strategies. Her past roles include Chief Marketing Officer at Plexus Worldwide and Senior Vice President at Shaklee Corporation.
LifeVantage Corporation (Nasdaq: LFVN) reported Q2 fiscal 2022 results, with revenue of $52.2 million, down 11.6% YoY and 1.9% sequentially. Active accounts fell 6.3% to 163,000, driven by a 17.1% drop in the Americas. Earnings per diluted share were $0.01, compared to $0.26 last year, while adjusted EBITDA decreased 71.6% to $1.9 million. The company repurchased 0.5 million shares for $3.2 million and ended the quarter with $20.2 million in cash and no debt. Guidance for fiscal 2022 has been lowered, anticipating revenues of $212-$220 million.
LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2021, on February 1, 2022, post-market close. A conference call for investors is scheduled for 2:30 PM MT (4:30 PM ET) the same day. Interested participants can join by dialing (877) 705-6003 or (201) 493-6725 for international callers. A replay will be available shortly after the call until February 8, 2022. LifeVantage focuses on nutrigenomics, offering products like Protandim® and Petandim®, with an emphasis on health and wellness.
LifeVantage Corporation (Nasdaq: LFVN) announced its participation in the 2022 ICR Conference on January 10 at 9:30 a.m. Eastern Time. The presentation will be accessible via a live webcast on the company's Investor Relations website.
LifeVantage specializes in nutrigenomics, focusing on how nutrition impacts health. Their product range includes dietary supplements, nootropics, and skincare. Notable products include the Protandim® family and the Axio® energy drink. For more details, visit the company's website.
